secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2025-01-17T23:59:59+00:00
Accession:  0001104659-25-004517
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq bid price compliance regained; equity compliance deadline extended to May 19
--------------------------------------------------------------------------------

- Cara regained Nasdaq minimum bid price compliance after 1-for-12 reverse stock split effective Dec 30; letter received Jan 16.
- Stockholders' equity of $707k at Sep 30 below $2.5M minimum; extension granted to May 19, 2025.
- Extension conditional on closing proposed merger with Tvardi, which is expected to meet initial listing criteria.
- Company must also satisfy all applicable Nasdaq initial listing standards at merger close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925004517/0001104659-25-004517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925004517/tm2430195d6_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-004517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer